Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/12/2018
SIETES contiene 92610 citas

 
 
 1 a 20 de 184 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Drugs and their names. Drug Ther Bull 2018;56:marzo. [Ref.ID 102507]
2. Cita con resumen
3. Cita con resumen
Anónimo. FDA Approves CAR-T therapy for treatment of childhood leukemia. DIA Daily 2017:1. [Ref.ID 102036]
4. Cita con resumen
Anónimo. Gilead agrees to acquire Kite Pharma in $11.9 billion deal. DIA Daily 2017:1. [Ref.ID 102034]
5. Cita con resumen
Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 2016;388:187-97. [Ref.ID 100623]
6. Cita con resumen
N.L.. Why gene-therapy drugs are so expensive. The Economist 2016:1. [Ref.ID 100562]
7. Cita con resumen
Anónimo. FDA grants experimental Huntington’s disease orphan drug status. DIA Daily 2016:1. [Ref.ID 100438]
8.Tiene citas relacionadas Cita con resumen
Stoessl AJ. Gene therapy for Parkinson's disease: a step closer?. Lancet 2014;383:1107-9. [Ref.ID 97375]
9.Tiene citas relacionadas Cita con resumen
Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas Ch, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Valle N, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 0;383:1138-46. [Ref.ID 97374]
10. Cita con resumen
Rice CM, Kemp K, Wilkins A, Scolding NJ. Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Lancet 2013;382:1204-13. [Ref.ID 96354]
11. Cita con resumen
12. Cita con resumen
Anónimo. FDA approves antisense therapy for HoFH. DIA Daily 2013:31 de enero. [Ref.ID 94643]
14.Tiene citas relacionadas
Ponder KP. Merry Christmas for patients with hemophilia B. N Engl J Med 2011;365:2426-31. [Ref.ID 91983]
15.Tiene citas relacionadas Cita con resumen
Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CYC, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Curringham JM, Srivastava D, Basner-Tschakarjan EB, Mingozzi F, High KA, Gray JT, Reiss UM, Nenhuis AW, Davidoff AM. Adenovirus-associated virus vector - Mediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-65. [Ref.ID 91981]
16. Cita con resumen
Anónimo. Vemurafenib (Zelboraf) for metastatic melanoma. Med Lett Drugs Ther 2011;53:77-8. [Ref.ID 91711]
17.
Morita H, Nagai R. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;365:1448. [Ref.ID 91549]
18. Cita con resumen
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggemont AMM, Dreno B, Nolop K, Nelson B, Jou J, Lee RJ, Flaherti KT, McArthur GA. Improved survival with vemarafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16. [Ref.ID 91354]
19. Cita con resumen
Anónimo. FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer . FDA U.S. Food and Drug Administration 2011:17 de agosto. [Ref.ID 91041]
Seleccionar todas
 
 1 a 20 de 184 siguiente >>